Nagib Ward previously held a variety of senior sales and marketing positions
at Novozymes North America Inc.
Paris, 8 July 2013 - DEINOVE (Alternext Paris: ALDEI), a clean technology company that designs, develops and markets a new generation of industrial processes based on the Deinococcus bacteria, is pleased to announce the nomination of Nagib Ward as Vice President Business Development.
As a member of the DEINOVE management team, Nagib Ward will be responsible for developing partnerships with manufacturers operating in the different markets targeted by DEINOVE, especially in the United States and Canada. He will also be instrumental in developing new markets for the company. Nagib Ward will be based in the United States.
"Having worked with Nagib at Novozymes for a number of years, I am extremely pleased that he has decided to join us", stated Emmanuel Petiot, Chief Executive Officer of Deinove. "Nagib has developed considerable expertise in the markets that we are targeting, such as 2nd generation biofuels and chemical bio-sourced compounds for specialty and commodity applications. He also has experience in commercializing technological innovation and is extremely familiar with the needs of our targeted industrial customers. Finally, his first-hand knowledge of US markets is of key strategic importance for the future development of DEINOVE. I am confident that the arrival of Nagib to head our commercial operations will accelerate the pace of our development", concluded Emmanuel Petiot.
Nagib Ward is 36 years old and graduated from Northern Michigan University with a Master of Science in Chemistry and Biochemistry and also holds an MBA from the Graduate School of Management of Marquette University. He has spent the past six years working at the Novozymes Group, world leader in enzymes and microorganisms. Whilst there, he held several senior sales and marketing positions in the biofuels, biomass, food and household care divisions. Prior to Novozymes, he was an R&D Senior Chemist at Appleton Papers Inc. Nagib Ward holds several Novozymes and Appleton patents and invention disclosures, and was two-time receiver of the Appleton Innovation Award (2004/2005). He clearly brings to DEINOVE a highly valuable set of scientific and marketing skills as well as a successful track record in launching new products and industrial processes.
About DEINOVE
DEINOVE (Alternext Paris: ALDEI) is a clean technology company that designs and develops new standards of production based on bacteria of untapped potential: the Deinococci.
Taking advantage of their unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce rare compounds or products that are technologically difficult to produce: 2nd generation biofuels (DEINOL) and chemical intermediates (DEINOCHEM), but also new antibiotics (DEINOBIOTICS project now led by the subsidiary DEINOBIOTICS SAS) or enzymes for the remediation of plastics (THANAPLAST(TM) project led by CARBIOS).
Listed on Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Professor Miroslav Radman, of the Faculty of Medicine of the University René Descartes. The company employs some 30 people and conducts R&D programs in partnership with the CNRS (Marseille and Montpellier), INSA (Toulouse) and VTT (Finland). DEINOVE'S headquarters and laboratories are located in Paris and at the Technoparc Cap Alpha, in Montpellier.
More information at www.deinove.com
Contacts
| DEINOVE Emmanuel PETIOT CEO Tel: + 33 1 42 03 27 37 emmanuel.petiot@deinove.com | Elisabetta CASTELLI Director of Communications and Investor Relations Mob.: +33 6 13 66 39 39 elisabetta.castelli@deinove.com |
| ATCG Press Marielle BRICMAN Press Relations Mob.: +33 6 26 94 18 53 deinove@atcg-partners.com |  |